Drugmakers that have bacitracin injections on the market include Pfizer, Mylan, Akorn and Fresenius Kabi, according to Regulatory Focus.
The FDA said the drug has serious risks, including kidney damage, severe allergic reactions and the need for repeated intramuscular injections.
The FDA’s antimicrobial drugs advisory committee voted last April, almost unanimously, that the risks outweigh the benefits for bacitracin injections, Regulatory Focus reported. The committee also said there are multiple safe and effective alternatives to treat pneumonia and empyema.
The FDA said Jan. 31 that it “believes that the potential problems associated with bacitracin for injection are sufficiently serious to remove the drug from the market.”
Read the full news release here.
More articles on pharmacy:
Overburdened pharmacists at top retail chains say they worry about patient safety
OptumRx’s drug trends to watch in 2020: 5 things to know
AmerisourceBergen closes PharMEDium unit, cuts 165 jobs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
